AstraZeneca Enhertu shows clinically meaningful, durable responses across multiple HER2-expressing tumour types in DESTINY-PanTumor02 Phase II trial Ruchika Sharma8 March 2023 7:30 AM GMTHER2 is a tyrosine kinase receptor protein expressed on the surface of various tissue cells throughout the body and is involved in normal cell
AstraZeneca-Daiichi Sankyo Enhertu approved in China for breast cancer Ruchika Sharma25 Feb 2023 8:00 AM GMTUK: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in China as a monotherapy for the treatment of adult...
Daiichi Sankyo ENHERTU gets Japanese nod for patients with previously treated HER2 Positive Metastatic Breast Cancer Ruchika Sharma25 Nov 2022 8:00 AM GMTENHERTU (trastuzumab deruxtecan, fam-trastuzumab deruxtecan-nxki in the U.S. only) is a HER2 directed ADC.
AstraZeneca- Daiichi Sankyo Enhertu recommended for nod in EU by CHMP for patients with previously treated HER2-positive advanced gastric cancer Ruchika Sharma15 Nov 2022 6:45 AM GMTEnhertu is a HER2-directed ADC.
Health Bulletin 23/August/2022 Roshni Dhar23 Aug 2022 11:48 AM GMTHere are the top health news for the day:'Tomato fever' misleading colloquial name for hand, foot and mouth disease Medical professional has informed...
AstraZeneca, Daiichi Sankyo get USFDA accelerated nod for Enhertu for HER2 Mutant Non-small Cell Lung Cancer Ruchika Sharma14 Aug 2022 10:00 AM GMTEnhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialised by AstraZeneca and Daiichi...
AstraZeneca Enhertu secures USFDA nod for HER2-low breast cancer Ruchika Sharma6 Aug 2022 9:00 AM GMTEnhertu is a HER2-directed ADC.
AstraZeneca, Daiichi Sankyo get USFDA nod for Enhertu for earlier breast cancer use Ruchika Sharma6 May 2022 11:38 AM GMTThe approval was granted under the FDA's Real-Time Oncology Review (RTOR) programme and converts the accelerated approval of Enhertu in later line...
Trastuzumab deruxtecan decreases risk of disease progression and death in HER2 positive breast cancer: NEJM Medical Dialogues Editorial Team30 March 2022 3:45 AM GMTUSA: A new study published in The New England Journal of Medicine shows that patients with human epidermal growth factor receptor 2 (HER2)-positive...
AstraZeneca gets CDSCO panel nod to conduct cancer drug Trastuzumab Deruxtecan study Medical Dialogues Team29 Nov 2021 12:51 PM GMTNew Delhi: In a significant development, major drug-maker AstraZeneca has got the go ahead from the Subject Expert Committee (SEC) functional under...
Daiichi Sankyo Launches ENHERTU in Japan for Patients with HER2 Positive Unresectable or Metastatic Breast Cancer Ruchika Sharma26 May 2020 7:23 AM GMTTokyo, Munich: Daiichi Sankyo Company, Limited has announced the launch of ENHERTU® (trastuzumab deruxtecan), a HER2 directed antibody drug conjugate...
AstraZeneca, Daiichi Sankyo get Orphan Drug Designation for gastric cancer drug Enhertu Ruchika Sharma25 May 2020 6:26 AM GMTUS: Daiichi Sankyo Company Limited and AstraZeneca's Enhertu (trastuzumab deruxtecan) has been granted Orphan Drug Designation (ODD) in the US for the...
